Centessa Pharmaceuticals PLC- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Centessa Pharmaceuticals PLC 公司

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Centessa Pharmaceuticals PLC简介



公司代码CNTA

公司名称Centessa Pharmaceuticals PLC

上市日期May 28, 2021

CEOSaha (Saurabh)

员工数量77

证券类型Depository Receipt

年结日May 28

公司地址3rd Floor

城市ALTRINCHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编WA14 2DT

电话447391789784

网址https://www.centessa.com/

公司代码CNTA

上市日期May 28, 2021

CEOSaha (Saurabh)

Centessa Pharmaceuticals PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Gregory M. (Greg) Weinhoff, M.D.

Chief Business Officer

77.08K

+16842.00%

Dr. Saurabh Saha, M.D., Ph.D.

Chief Executive Officer, Director

45.17K

--

Mr. Iqbal Hussain

General Counsel and Chief Compliance Officer, Company Secretary

--

Ms. Tia Bush

Chief Technology and Quality Officer

--

Dr. Francesco de Rubertis, Ph.D.

Non-Executive Independent Chairman of the Board

--

Dr. Arjun Goyal, M.D.

Non-Executive Independent Director

--

Dr. Brett I. W. Zbar, M.D.

Non-Executive Independent Director

--

Dr. Mary Lynne Hedley, Ph.D.

Non-Executive Independent Director

--

Dr. Samarth Kulkarni, Ph.D.

Non-Executive Independent Director

--

Ms. Carol Stuckley

Non-Executive Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Gregory M. (Greg) Weinhoff, M.D.

Chief Business Officer

77.08K

+16842.00%

Dr. Saurabh Saha, M.D., Ph.D.

Chief Executive Officer, Director

45.17K

--

Mr. Iqbal Hussain

General Counsel and Chief Compliance Officer, Company Secretary

--

Ms. Tia Bush

Chief Technology and Quality Officer

--

Dr. Francesco de Rubertis, Ph.D.

Non-Executive Independent Chairman of the Board

--

Dr. Arjun Goyal, M.D.

Non-Executive Independent Director

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 1月18日周日

持股股东

股东类型

持股股东

占比

Medicxi Ventures (UK) LLP

13.67%

Avoro Capital Advisors LLC

7.40%

Adage Capital Management, L.P.

6.87%

Index Ventures SA

6.82%

General Atlantic LLC

5.04%

其他

60.19%

持股股东

占比

Medicxi Ventures (UK) LLP

13.67%

Avoro Capital Advisors LLC

7.40%

Adage Capital Management, L.P.

6.87%

Index Ventures SA

6.82%

General Atlantic LLC

5.04%

其他

60.19%

股东类型

持股股东

占比

Venture Capital

21.32%

Investment Advisor/Hedge Fund

20.31%

Hedge Fund

19.37%

Investment Advisor

16.87%

Private Equity

8.07%

Research Firm

1.42%

Individual Investor

0.61%

Bank and Trust

0.03%

Pension Fund

0.01%

其他

12.00%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

255

127.66M

87.41%

-17.58M

2025Q3

241

133.90M

109.10%

+4.79M

2025Q2

226

132.04M

110.14%

-1.07M

2025Q1

214

132.76M

108.57%

-12.24M

2024Q4

180

128.06M

101.80%

+5.92M

2024Q3

158

122.07M

88.34%

+22.15M

2024Q2

135

99.90M

89.43%

+12.17M

2024Q1

129

87.74M

96.45%

-9.01M

2023Q4

114

84.27M

95.12%

+1.65M

2023Q3

113

82.62M

96.02%

+2.24M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Medicxi Ventures (UK) LLP

19.96M

13.67%

--

Sep 30, 2025

Avoro Capital Advisors LLC

10.81M

7.4%

+5.81M

+116.16%

Sep 30, 2025

Adage Capital Management, L.P.

10.04M

6.87%

+1.63M

+19.42%

Sep 30, 2025

Index Ventures SA

9.96M

6.82%

--

Sep 30, 2025

General Atlantic LLC

7.37M

5.04%

-2.31M

-23.91%

Nov 26, 2025

Fidelity Management & Research Company LLC

6.24M

4.27%

+2.41M

+63.08%

Sep 30, 2025

Janus Henderson Investors

5.41M

3.7%

-1.12M

-17.21%

Sep 30, 2025

T. Rowe Price Associates, Inc.

4.80M

3.29%

-1.10M

-18.69%

Sep 30, 2025

Farallon Capital Management, L.L.C.

4.33M

2.97%

-198.00K

-4.37%

Sep 30, 2025

First Light Asset Management, LLC

3.64M

2.49%

-657.60K

-15.32%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

3.56%

Virtus LifeSci Biotech Clinical Trials ETF

1.4%

Invesco Nasdaq Biotechnology ETF

0.23%

ProShares Ultra Nasdaq Biotechnology

0.23%

T Rowe Price Small-Mid Cap ETF

0.15%

iShares Biotechnology ETF

0.13%

Fidelity Fundamental Small-Mid Cap ETF

0.11%

iShares Intl Small Cap Equity Factor ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0.01%

SPDR S&P International Small Cap ETF

0%

iShares Neuroscience and Healthcare ETF

占比3.56%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.4%

Invesco Nasdaq Biotechnology ETF

占比0.23%

ProShares Ultra Nasdaq Biotechnology

占比0.23%

T Rowe Price Small-Mid Cap ETF

占比0.15%

iShares Biotechnology ETF

占比0.13%

Fidelity Fundamental Small-Mid Cap ETF

占比0.11%

iShares Intl Small Cap Equity Factor ETF

占比0.01%

Fidelity Nasdaq Composite Index ETF

占比0.01%

SPDR S&P International Small Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据